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Complex I (NADH:ubiquinone oxidoreductase) is the ﬁrst and largest multimeric complex of the mitochondrial respiratory chain.
Human complex I comprises seven subunits encoded by mitochondrial DNA and 38 nuclear-encoded subunits that are assembled
together in a process that is only partially understood. To date, mutations causing complex I deﬁciency have been described in all
14 core subunits, ﬁve supernumerary subunits, and four assembly factors. We describe complex I deﬁciency caused by mutation of
the putative complex I assembly factor C20orf7. A candidate region for a lethal neonatal form of complex I deﬁciency was identiﬁed
by homozygosity mapping of an Egyptian family with one affected child and two affected pregnancies predicted by enzyme-based
prenatal diagnosis. The region was conﬁrmed by microcell-mediated chromosome transfer, and 11 candidate genes encoding potential
mitochondrial proteins were sequenced. A homozygous missense mutation in C20orf7 segregated with disease in the family. We show
that C20orf7 is peripherally associated with the matrix face of the mitochondrial inner membrane and that silencing its expression with
RNAi decreases complex I activity. C20orf7 patient ﬁbroblasts showed an almost complete absence of complex I holoenzyme and were
defective at an early stage of complex I assembly, but in amanner distinct from the assembly defects caused bymutations in the assembly
factor NDUFAF1. Our results indicate that C20orf7 is crucial in the assembly of complex I and that mutations in C20orf7 cause
mitochondrial disease.Introduction
Mitochondrial energy-generation disorders affect at least 1
in 5000 births1 and can be caused by mutations in nearly
100 different genes.2 Respiratory chain complex I (NADH-
ubiquinone oxidoreductase) deﬁciency (MIM 252010) is
the most commonly diagnosed energy-generation disor-
der.3,4 It has a wide range of clinical presentations and
disease onset3,5,6 andhas alsobeen implicated inmore com-
mon neurological disorders such as Parkinson’s disease.7
Complex I is the major entry point of electrons into the
mitochondrial electron-transport chain and contributes to
the establishment of a proton gradient that is required for
ATP synthesis. Human complex I is the ﬁrst and most
complicated of the respiratory-chain complexes and is
composed of seven subunits encoded by mitochondrial
DNA (mtDNA) and 38 nuclear-encoded subunits, which
are assembled into a large complex of ~950 kDa.8 It further
assembles into higher-ordered supercomplexes or ‘‘respira-
somes’’ with respiratory-chain complexes III and IV.9,10 Al-
though all of its subunits have been identiﬁed, we have
only a partial understanding of how the massive complex
I assembles and which proteins aid this process.11Mutations causing complex I deﬁciency have been iden-
tiﬁed in 23 genes, with most detected in only a small num-
ber of families. These genes encode the 14 core subunits of
complex I, comprising seven nuclear genes (NDUFS1 [MIM
157655], NDUFS2 [MIM 602985], NDUFS3 [MIM 603846],
NDUFS7 [MIM 601825], NDUFS8 [MIM 602141], NDUFV1
[MIM 161015], and NDUFV2 [MIM 600532])12–18 and all
seven mtDNA subunit genes.3,19,20 Pathogenic mutations
have also been identiﬁed in genes encoding ﬁve supernu-
merary subunits, NDUFS4 (MIM 602694),21 NDUFS6
(MIM 603848),22 NDUFA1 (MIM 300078),23 NDUFA1124
and NDUFA2 (MIM 602137);25 three assembly factors,
NDUFAF2 (B17.2L) (MIM 609653),26 NDUFAF1 (CIA30)
(MIM 606934),27 andC6orf66 (MIM 611776);28 and a puta-
tive new assembly factor, C8orf38.29 Mutations in mtDNA
appear to account for approximately one-quarter of com-
plex I deﬁciency,19,20 and mutations in all the reported
mtDNA and nuclear genes appear to explain only about
half of the cases.30 Therefore, these data suggest that the
remaining mutations reside in unknown genes encoding
additional factors involved in complex I biogenesis.
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and two affected fetuses of an Egyptian family. We show
that C20orf7 is a mitochondrial inner-membrane protein
with a role in the early stages of complex I assembly. There-
fore, we have identiﬁed mutations in a ﬁfth assembly
factor of complex I as a cause of complex I deﬁciency.
Material and Methods
Subjects
The clinical presentation of the proband was reported previ-
ously.31 He was the ﬁrst child of ﬁrst-cousin Egyptian parents
and presented with lethal neonatal mitochondrial disease. He
was born at 35 weeks gestation and suffered from intrauterine
growth retardation. He had minor facial dysmorphism, and other
minor dysmorphic features included unusual hair patterning,
abnormal toes, and a small sacral pit. Cerebral ultrasound showed
agenesis of the corpus callosum and ventricular septation. He also
had a congenital left diaphragmatic hernia. Adrenal insufﬁciency
resulted in persistent hypotension. His initial blood lactate level
was 3.1 mM on day 5, which rose to 16.5 mM within 24 hr,
with pyruvate 0.15 mM (lactate/pyruvate ratio of 110). Cerebro-
spinal ﬂuid (CSF) lactate at this time was 20.1 mM, with pyruvate
0.34 mM. Urinary alanine was also elevated. He had normal liver
and renal function. Histology of skeletal muscle showed no
speciﬁc abnormalities. He died of cardiorespiratory arrest due to
progressive lactic acidosis on day 7 and was diagnosed with an iso-
lated complex I defect. Subsequently, four enzyme-based prenatal
diagnoses were undertaken: Two affected pregnancies were termi-
nated and two unaffected pregnancies resulted in healthy chil-
dren. The proband and affected siblings were reported as patients
A, A2, and A3, respectively, in a previous study.22 This study was
approved by the Royal Children’s Hospital Ethics in Human
Research Committee.
Cell Culture and Complex I Enzyme Assays
Cell culture and assays for respiratory-chain enzymes and citrate
synthase (CS) were performed as described3,32 with cultured cell
mitochondria and post-600 g supernatants prepared from muscle
and other tissues. Complex I-linked ATP synthesis was assessed in
permeabilized cells by measurement of the ratio of ATP synthesis
using glutamate plus malate (complex I substrate) with that using
succinate and rotenone (complex II substrate) as described
previously.3
Microcell-Mediated Chromosome Transfer
Primary ﬁbroblasts from patients and a healthy control were
transduced with a retroviral vector expressing the E6E7 region of
type 16 human papilloma virus to extend their life span.33 A cell
line from a panel of human-mouse monochromosomal hybrids34
was used as the donor of normal human chromosome 20. Chro-
mosome 20 was transferred into the E6E7-transduced patient
cell line by microcell-mediated chromosome transfer (MMCT), as
described previously,33 following the modiﬁed protocol described
elsewhere.22
Genotyping
Genome-wide scans, ﬁne mapping, and genotyping of parental
cell lines and clones were performed at the Australian Genome Re-
search Facility (Melbourne, Victoria, Australia) with 377 and 3700
DNA sequencers (Applied Biosystems). Data were analyzed withThe AmeriGeneScan Analysis version 3.1.2 and Genotyper version 2.1 soft-
ware (Applied Biosystems). Genome-wide scans were performed
on puriﬁed DNA with the LMS2-HD5 marker set (Applied Biosys-
tems), which has 811 microsatellite markers spread at an average
genetic distance of 5 cM. Additional markers were used for ﬁne
mapping of the causative locus.
Bioinformatic Analysis
The likelihood of mitochondrial localization of proteins encoded
by all RefSeq genes in the candidate region was initially predicted
with methods described elsewhere.35 Additionally, candidate
genes were compared with a set of 19 genes that we recently
identiﬁed as showing correlated evolution with a set of complex
I subunits.29
Mutation Analysis and DNA Sequencing
Exons from 11 transcripts were sequenced: C20orf7 (AK091060,
NM_024120.1, NM_024120.3), C20orf72 (NM_052865), HSPC072
(NM_014162), SNRPB2 (NM_198220, NM_003092), SEC23B
(NM_032986, NM_006363, NM_032985), SNX5 (NM_014426,
NM_152227), DSTN (NM_006870, NM_0010011546), C20orf133/
MACROD2 (NM_080676), ZNF339/OVOL2 (NM_021220),
C20orf79 (NM_178483), and RBBP9 (NM_006606, NM_153328).
Primary ﬁbroblasts were grown for 24 hr in 100 mg/ml cyclohexi-
mide prior to preparation of RNA in order to minimize nonsense-
mediated mRNA decay.36 RNA was reverse transcribed into cDNA
with Superscript III reverse transcriptase via an RT-PCR kit (Invitro-
gen). Automated sequencing was performed on shrimp alkaline
phosphatase-treated PCR products (ExoSAP-IT; USB Corp.) via a
BigDye Terminator Cycle Sequencing kit (Applied Biosystems).
The sequencing reactions were puriﬁed with DyEx columns
(QIAGEN). Electrophoresis was performed on an Applied Biosys-
tems Prism 3100 Genetic Analyzer at Applied Genetic Diagnostics
(University of Melbourne). Sequence data were analyzed with
Chromas (Technelysium Pty.) software version 1.51 and compared
with the RefSeq sequence.
All exons of C20orf7 were ampliﬁed from genomic DNA with
primers that incorporated at least 30 bp of 50 and 30 intronic
sequence (Table 1 available online). The entire coding region of
C20orf7 was also ampliﬁed from cDNA. Wild-type and variant
C20orf7 alleles were distinguished by a PCR-RFLP test utilizing
a BstNI site introduced by the c.719T/C mutation.
RNA Interference and Measurement
of Complex I Activity
Lentiviral vectors (pLKO.1) containing short-hairpin sequences
targeted against C20orf7 were obtained from the Broad RNAi
Consortium (TRC).37 Virus production and infection of MCH58
human ﬁbroblast cells was performed as recently reported.29
Knockdown efﬁciency was assessed via real-time PCR (Applied
Biosystems Taqman Assays) with beta actin as an endogenous con-
trol after growth for ~2 weeks in puromycin-containing medium.
For immunoblot analysis of complex I and complex IV subunits,
10 mg of protein from cleared whole-cell lysate was separated on
a 4%–12% SDS-PAGE gel (Invitrogen) and transferred to polyviny-
lidene ﬂuoride membrane. Membranes were probed with anti-
bodies raised against MTCO2 (Mitosciences), an 8 kDa complex I
subunit (Mitosciences), and beta actin (Sigma). Complex I and
complex IV activity assays were performed with immunocapture-
based dipstick assays (Mitosciences). Fifteen micrograms of
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whole-cell lysate were used for each assay following the manufac-
turer’s protocol. Results were scanned with a BioRad GS-800
scanner and analyzed with Quantity One software.
Figure 1. Residual Complex I Activity
in Affected and Unaffected Individuals
of Family A
Individuals A1, A3, and A4 are affected,
and individuals A2 and A5 are unaffected.
Complex I activity is expressed relative to
citrate synthase activity (I/CS), as a per-
centage of the control mean for each
tissue. The observed ranges for controls
are represented by the vertical bars. CVS
denotes chorionic villus cells.
ucts, blue-native (BN) PAGE, and two-
dimensional (2D) and Tris-tricine SDS-
PAGE were performed as previously
described.42 Western blotting was per-
formed with a semidry transfer method.43
Immunoreactive proteins from blots were
detected with a ChemiGenius BioImaging
system (SynGene) using horse-radish
peroxidase coupled secondary antibodies (Sigma) and ECL
substrate (GE).In Vitro Protein Import into Isolated Mitochondria
Radiolabeled C20orf7 protein was translated from pGEM-4Z plas-
mid DNA containing the C20orf7 transcript via the TnT Coupled
Reticulocyte Lysate System (Promega) in the presence of 35S-methi-
onine and 35S-cysteine (EXPRE35S35S Protein Labeling Mix; Perkin
Elmer Life Sciences, USA). Translated protein was incubated with
mitochondria isolated fromHT1080 cells at 37C for various times
as indicated. Proteinase K treatment and dissipation of mitochon-
drialmembranepotentialwereperformedasdescribedelsewhere.38
C20orf7 Mitochondrial Localization
COS-7 cells were transfected with plasmid DNA containing
a FLAG-tagged C20orf7 transcript by use of Lipofectamine 2000
(Invitrogen). Mitochondria were isolated and subjected to either
sonication in 100 mM NaCl,10 mM Tris-HCl (pH 7.6) or alkaline
extraction in freshly prepared 0.1M Na2CO3 (pH 11.5).
39 Mem-
branes were pelleted at 100,000 3 g for 30 min at 4C, and super-
natants were precipitated with the addition of 1/5 volume of 72%
trichloroacetic acid. After treatments, soluble (S, supernatant) and
insoluble (P, pellet) fractions were subjected to SDS-PAGE and
western-blot analysis using antibodies against FLAG (to detect
C20orf7-FLAG), NDUFB6, and cytochrome c.
Antibodies
Monoclonal antibodies against the complex III subunit core 1,
complex IV subunit II, complex V a-subunit, and the complex II
70 kDa subunit were from Molecular Probes, and antibodies to
the complex I 8 kDa subunit were from Mitosciences. Antibodies
against cytochrome c (BD Biosciences), VDAC1 (Abcam), and
FLAG (Sigma) were also obtained from commercial sources. Poly-
clonal antibodies against NDUFA9 and NDUFB6 were raised in
rabbits as previously described.40
Other Methods
Mitochondria were isolated from cultured cells as previously
described.41 Radiolabeling of mitochondrial translation prod-470 The American Journal of Human Genetics 83, 468–478, OctobeResults
Biochemistry, Homozygosity Mapping,
and Candidate-Gene Analysis
Respiratory-chainenzymeanalysis showedmarkedcomplex
I deﬁciency in skeletal muscle, liver, and skin ﬁbroblasts of
the proband, with essentially normal activity of other com-
plexes.31 Prenatal diagnosis was undertaken in four subse-
quent pregnancies by enzyme and functional analysis of
cultured chorionic villus cells. Two affected pregnancies
were diagnosed by ﬁnding values of complex I activity and
complex I-linked ATP synthesis that were < 30% of control
values (ATP synthesis not shown). The affected pregnancies
were terminated and complex I deﬁciencywas conﬁrmed in
fetal skin ﬁbroblasts or tissues. Two unaffected pregnancies
resulted in the birth of healthy children (Figure 1).
Previous analysis with BN-PAGE and western blotting
showed the absence of fully assembled complex I in ﬁbro-
blasts from the proband.22 A 5 cM genome-wide scan of
811 microsatellite markers in the three affected individuals
and their parents identiﬁed only seven markers that were
homozygous in the three affected individuals but not in
the parents. In addition, there were 42 autosomal homozy-
gousmarkers that were not informative, i.e., were homozy-
gous in one or both parents. Three of the seven informa-
tive markers were located adjacent to each other on
chromosome 20p, making it the largest homozygous
region shared exclusively by all three affected individuals
and not by healthy family members. Fine mapping of all
seven family members with additional microsatellite
markers narrowed the candidate region to 9.2 Mb between
D20S894 and D20S471 (Figure 2).
Microcell-mediated chromosome transfer was used to
determine whether introducing a normal copy ofr 10, 2008
chromosome 20 into a patient cell line could restore
complex I levels. Phenotypic correction was assessed by
SDS-PAGE western blotting with antibodies to two com-
plex I subunits that were grossly decreased in patient cell
lines. Clones were classiﬁed as corrected, uncorrected, or
ambiguous on the basis of at least two independent west-
ern blots. Figure 3 shows examples for two clones, one of
which has corrected complex I subunit levels to near-nor-
mal levels whereas the other has not. Of 14 tested clones,
four had normalized complex I subunit levels, ﬁve did
not, and ﬁve gave ambiguous results. These data conﬁrm
that the causative locus is on chromosome 20. Uncorrected
clones were genotyped with microsatellite markers and
Affymetrix 50K XbaI SNP chips, which conﬁrmed that at
least two clones had deleted all or part of the candidate
Figure 2. Pedigree and Haplotypes of Family Members
Genotyped markers from the chromosome 20p region between
D20S894 and D20S471 are shown to the left, and each individual’s
allele numbers are listed. The three homozygous markers from the
original genome-wide scan are shown in gray. The largest homozy-
gous region shared exclusively by the three affected siblings is
boxed, and the proband is indicated by the arrow.The Americregion (not shown). However, these data did not provide
signiﬁcant narrowing of the candidate region.
To begin searching for a candidate gene in this interval
that may underlie the observed complex I deﬁciency, we
performed gene-expression analysis with Compugen 19K
Human Oligoarrays and Codelink 50K Human Bioarrays.
However, no transcripts within the region showed signiﬁ-
cant differential expression (data not shown).
The causative mutation for this deﬁciency is most likely
in a gene encoding amitochondrial protein. We previously
described an integrative genomics approach to predict the
probability of any gene encoding a mitochondrial-local-
ized protein.35 This approach combines predictions of mi-
tochondrial-targeting sequence, protein-domain enrich-
ment, presence of cis-regulatory motifs, yeast homology,
ancestry, tandem-mass spectrometry, coexpression, and
transcriptional induction during mitochondrial biogene-
sis. Eleven of 29 RefSeq genes in the candidate region
were predicted to encode possible mitochondrial proteins
and were sequenced. Ten of the sequenced genes had
either no sequence variants or contained only RefSNPs or
variants that were not predicted to change conserved
amino acids or affect splicing. Only one gene, C20orf7,
contained a putative pathogenic sequence variant. Inter-
estingly, we also identiﬁed C20orf7 recently in an indepen-
dent phylogenetic analysis as being one of 19 genes that
had a shared evolutionary history with complex I subunits
and were therefore likely to be important for the function
of complex I.29
Mutation Analysis of C20orf7 Transcripts
Two NCBI RefSeq transcripts of C20orf7 (NM_024120.3 and
NM_001039375.1) are present. Both transcripts encode pro-
teins that are 96.4% identical and are predicted tobe imported
into mitochondria. NM_024120.3 is slightly longer and has
somewhat higher homology to its orthologs (on the basis of
BLASTp). Therefore, allnomenclature in thismanuscript refers
to NM_024120.3 and its protein NP_077025.
Genomic DNA sequencing analysis of the patient
revealed a homozygous missense mutation in exon 7 of
NM_024120.3: c.719T/C, leading to substitution of
Figure 3. SDS-PAGE Western Blotting of MMCT Clones
Antibodies against complex I 39 kDa (NDUFA9) and 17 kDa
(NDUFB6) subunits were used as well as VDAC (porin, as loading
control). Detectable protein in one corrected clone (c9) and one
uncorrected clone (b11) are shown in comparison to control (C)
and patient A4.an Journal of Human Genetics 83, 468–478, October 10, 2008 471
Figure 4. Mutation Analysis of C20orf7
Nomenclature is based on NM_024120.3.
(A) Sequencing chromatograms showing
the c.719T/C mutation in the proband’s
genomic DNA, which predicts a Leucine-
to-Proline substitution at codon 229.
(B) Amino acid alignment of C20orf7
orthologs shows that Leu229 and the
surrounding region are highly conserved
(gray shading). The alignment of the
mutated region was generated with Clus-
talW via sequences obtained from BLASTp
with both human transcripts: NP_077025
and NP_001034464. Sequences are from
Pongo pygmaeus (orangutan, accession
number CAH90789), Pan troglodytes (chim-
panzee, XP_514521), Bos taurus (bovine,
XP_600505), Canis familiaris (dog,
XP_534340), Rattus norvegicus (rat,
XP_215857), Mus musculus (mouse,
NP_081369), Xenopus tropicalis (frog,
NP_001016398), Drosophila melanogaster
(fruit fly, AAL29045), A. gambiae str.
PEST (mosquito, EAA05526), Gibberella
zeae PH-1 (fungus, EAA70416), Neurospora
crassa (fungus, CAD11326).
(C) BstNI restriction-enzyme-based analy-
sis of the mutation in genomic DNA from
family members shows that only DNA from
affected individuals is homozygous for
the BstNI site introduced by the mutation.
The parents and one unaffected sibling are
heterozygous, and one unaffected sib is
homozygous for the wild-type allele.leucine 229 in the C20orf7 protein to proline (Figure 4A).
Leucine 229 is located within a region of the protein that
is highly conserved between different species from human
to fungus (Figure 4B), and its mutation to proline is pre-
dicted to alter secondary structure by breaking an alpha
helix (SOPM,44 data not shown). This putative pathogenic
homozygous mutation is also contained within the
NM_001039375.1 sequence (Figure 4B: NP_001034464).
Restriction fragment length polymorphism (RFLP)
analysis showed that homozygosity for the c.719T/C
substitution segregated with disease in the pedigree (Fig-
ure 4C), although the same would be expected for all vari-
ants in the candidate region. The c.719T/C substitution
was not present in 114 Australian or 210 Egyptian alleles.
C20orf7 was sequenced in a further 52 unrelated patients
with complex I deﬁciency in whom no molecular diagno-
sis had been achieved previously. No further patients with
a pathogenic C20orf7 mutation were identiﬁed.
C20orf7 Is an Inner-Mitochondrial-Membrane Protein
C20orf7 has a predictedN-terminalmitochondrial leader se-
quence (Mitoprot II, probability of mitochondrial import ¼
0.986),45 and its mitochondrial localization is supported
by GFP-tagging and microscopy.29 For conﬁrmation of its
mitochondrial location, in vitro transcription and transla-472 The American Journal of Human Genetics 83, 468–478, Octobetion was performed in the presence of 35S-methionine and
35S-cysteine. Radiolabeled C20orf7 was incubated with
isolated mitochondria for various times with import mon-
itored by SDS-PAGE (Figure 5A). The full-length 39 kDa
translation product (‘‘p,’’ precursor) can be seen in the
lysate (Figure 5A, lane 1) and associated with the mito-
chondria (Figure 5A, lanes 2 to 5). C20orf7 was cleaved
to its mature form (‘‘m’’) after incubation (Figure 5A, lanes
2–4 and 6–8). This mature form is protected from protein-
ase K treatment (Figure 5A, lanes 6 to 9), indicating that it
has been imported into the mitochondria. Furthermore,
the import of C20orf7 is dependent on an intact mem-
brane potential (Figure 5A, lanes 5 and 9), suggesting
that it resides within the mitochondrial matrix, where it
is processed by proteases.39
The submitochondrial location of C20orf7 was investi-
gated by transfection of COS-7 cells with a FLAG-tagged
C20orf7 construct, followed by incubation for 24 hr to
allow for protein expression. Mitochondria were isolated
and either sonicated or subjected to alkaline extraction
with sodium carbonate (Figure 5B). A FLAG antibody was
used to detect the C20orf7-FLAG protein. C20orf7 was
detected in the pellet (Figure 5B, ‘‘p,’’ lane 1) and not the
supernatant (Figure 5B, ‘‘s,’’ lane 2) after sonication, indi-
cating membrane localization. Conversely, the proteinr 10, 2008
was found in the supernatant (Figure 5B, ‘‘s,’’ lane 5) and
not the pellet (Figure 5B, ‘‘p,’’ lane 4) after alkaline extrac-
tion, suggesting that C20orf7 is only peripherally associ-
ated with the membrane. A membrane-arm subunit of
complex I (NDUFB6) and the intermembrane space pro-
tein cytochrome c were used as controls. The combined
import and western-immunoblotting results suggest that
C20orf7 resides on the matrix side of the inner membrane,
consistent with its putative role in complex I biogenesis.
C20orf7 Knockdown Decreases Complex I Activity
We next tested whether directly knocking down the levels
of C20orf7 would cause complex I deﬁciency. MCH58 cells
were stably transduced with lentiviral constructs contain-
ing short hairpin sequences. Control experiments utilized
hairpins designed against the NDUFAF1 gene encoding the
CIA30 complex I assembly factor. Knockdown efﬁciency
was assessed by real-time PCR assays using beta actin as
an endogenous control, and more than 80% knockdown
was achieved for both genes (data not shown). The activi-
ties of complexes I and IV were assessed ﬁrst by immuno-
capture-based activity assays, which showed that both
C20orf7 and NDUFAF1 hairpins caused a similar gross de-
crease in complex I activity, with a moremodest inhibition
of complex IVactivity (Figure 6A). SDS-PAGE immunoblot-
Figure 5. Mitochondrial Import and Localization of C20orf7
(A) [35S]-labeled precursor forms of C20orf7 were incubated with
mitochondria isolated from HT1080 cells at 37C for the time
points indicated in the presence and absence of a mitochondrial
membrane potential (Dcm). Samples were treated with and with-
out proteinase K (PK, 50 mg/ml) before SDS–PAGE and phosphor-
imager analysis to detect the precursor (p) and mature (m)
proteins.
(B) COS-7 cells were transfected with plasmid DNA containing
a FLAG-tagged C20orf7 construct. Isolated mitochondria were
subjected to either sonication, alkaline (carbonate, Na2CO3)
extraction, or no treatment (Con). After treatments, soluble (S)
and insoluble (P) fractions were subjected to SDS-PAGE and west-
ern-blot analysis using antibodies against FLAG, NDUFB6 17 kDa
complex I subunit, and cytochrome c.The Americting conﬁrmed that the C20orf7 hairpin caused a gross de-
crease in the steady-state level of the 8 kDa complex I sub-
unit but no obvious effect on the levels of VDAC or the
MTCO2 complex IV subunit (Figure 6B). These data
strongly suggest that C20orf7 is crucial for activity and/
or assembly of endogenous complex I.
C20orf7 Is Involved Early in Complex I Assembly
Patient A4 ﬁbroblasts had been previously shown to
almost completely lack the mature complex I holoenzyme
by BN-PAGE immunoblotting.22 To examine whether the
loss of complex I is due to an assembly defect or increased
turnover, we radiolabeled mtDNA-encoded subunits and
monitored their assembly into various complexes with
BN-PAGE (Figure 7A). In control ﬁbroblasts, mature com-
plex I is clearly detectable after 24 hr chase (Figure 7A,
lane 4), with some mature complex weakly detectable after
only 6 hr chase (Figure 7A, lane 3). However, in patient A4
ﬁbroblasts, no complex I was detectable after 24 hr chase
(Figure 7A, lane 8), suggesting a defect in the assembly of
mtDNA-encoded subunits into complex I. The assembly
of complex IV, complex V, and the complex III homodimer
(III2) in patient A4 was comparable to the assembly in
control ﬁbroblasts (Figure 7A).
Immunoblot analysis was also performed with anti-
bodies against subunits of the respiratory complexes.
Steady-state levels of complex I are reduced in patient A4
(Figure 7B, lane 10) compared to control (Figure 7B, lane
9), whereas levels of complex IV, the complex III dimer
(CIII2), complex V, and the complex III2/IV supercomplex
were all similar in patient A4 (‘‘P’’) compared to control
(‘‘C’’).
To further examine the potential assembly defect in
patient A4 ﬁbroblasts, we analyzed the assembly proﬁles
of radiolabeled mtDNA-encoded subunits by using two-
dimensional BN-PAGE analysis.42 It has been previously
established that the ND2 subunit of complex I assembles
into a ~460 kDa intermediate complex before assembling
into an ~830 kDa intermediate that includes the ND1 sub-
unit. At later times, these subunits assemble into holocom-
plex I.11 In control ﬁbroblasts (Figure 7C, left panels), ND1
andND2 are found in the ~460 kDa and ~830 kDa interme-
diate complexes at early chase times (0 and 3 hr), whereas
at 24 hr chase these two subunits assemble into the mature
complex (CI). In patient A4, ND2 was present in the ~460
kDa complex at 0 and 3 hr chase, but it did not assemble
into the ~830 kDa complex (Figure 7C,middle panels). Fur-
thermore, ND1 (or an intermediate complex containing
ND1) was not present at these early chase times, suggesting
that this assembly step was defective. At 24 hr chase, no
complex I had assembled in patient A4 mitochondria,
and the ND2 intermediate complex was lost, presumably
turned over (Figure 7C, middle panel, bottom). This assem-
bly defect is distinct from that seen in patient P, who har-
bors a CIA30 (NDUFAF1) defect.27 In this case, the interme-
diate complex containing ND2 is absent at 0 and 3 hr
chase, whereas ND1 is present but remains stalled inan Journal of Human Genetics 83, 468–478, October 10, 2008 473
Figure 6. Knockdown of C20orf7 by
RNA Interference Disrupts Complex I
(A) MCH58 cells were infected with lentivi-
rus containing constructs encoding hair-
pins against the indicated targets. After
growth for 2 weeks in puromycin-contain-
ing selection medium, cells were lysed
and immunocapture-based activity assays
for complexes I and IV were performed in
duplicate. Activity is normalized to GFP
control, with error bars representing the
observed range of duplicate estimates.
(B) For western analysis, 4 mg of a mito-
chondria-enriched fraction from the indi-
cated knockdown cell lines were separated by SDS-PAGE, transferred to PVDF membranes, and blotted with antibodies against VDAC1,
a complex IV subunit (MTCO2), or a complex I subunit previously shown to correlate with complex I disassembly (8 kDa subunit).an ~400 kDa complex (Figure 7C, right panels). At 24 hr
chase, complex I assembly was not detectable, and both
ND1 and ND2 were lost (Figure 7C, right panels). These re-
sults suggest that C20orf7 is involved in the assembly or
stability of an early complex I assembly intermediate that
contains (among others) the ND1 subunit.
Discussion
We studied a consanguineous Egyptian family in which
one child and two pregnancies were affected by complex
I deﬁciency. Homozygosity mapping identiﬁed a 9.2 Mb
region on chromosome 20p as being the largest region
that was identical by descent in the three affected siblings.
Transfer of a normal copy of chromosome 20 into a patient
cell line bymicrocell-mediated chromosome transfer could
correct complex I activity, conﬁrming that the causative
gene was located on chromosome 20. Genes within the
candidate region were prioritized by bioinformatic analy-
ses, and 11 genes encoding known or predicted mitochon-
drial proteins were sequenced. Only one possibly patho-
genic mutation was identiﬁed, a homozygous c.719C/T
mutation present in both predicted transcripts of
C20orf7. This mutation was not found in 210 Egyptian
control alleles and is predicted to cause the substitution
of a highly conserved leucine residue to proline, probably
affecting C20orf7 protein structure. We showed that
C20orf7 was imported into mitochondria, where it is local-
ized on the matrix side of the inner membrane. Knock-
down of C20orf7 expression via lentiviral-mediated RNAi
caused marked decrease in complex I activity, conﬁrming
that lack of C20orf7 can cause complex I deﬁciency.
Complex IV activity and the amount of the complex IV
subunit MTCO2 showed a modest decrease after C20orf7
shRNA treatment, and a more marked decrease after
NDUFAF1 shRNA treatment. This raises the possibility
that both proteins may play a role in complex IV assembly
or that efﬁcient assembly or stability of complex IV may
depend on normal complex I or supercomplex assembly.
A similar loss of complex IV activity and protein has474 The American Journal of Human Genetics 83, 468–478, Octobebeen noted previously in transgenic Caenorhabditis elegans
strains expressing mutations in the NDUFV1 complex I
subunit.46 However, this issue remains unresolved because
all tissues and cell lines studied from patients with muta-
tions in the C20orf7 or NDUFAF1 genes have shown essen-
tially normal complex IV activity.27 Secondary effects on
complex IV assembly may only occur in some tissues and
with speciﬁc types or severity of complex I defects.
Extensive proteomic studies have led to the conclusion
that the complex I holoenzyme comprises 45 known
subunits.8 C20orf7 is not one of these subunits, so it pre-
sumablyplays a role in complex I assemblyormaintenance.
Steady-state mRNA transcripts for C20orf7 have been de-
tected in 79 human tissues,47 implying that the protein is
widely expressed.C20orf7possesses a predicted S-adenosyl-
methionine (SAM)-dependent methyltransferase fold, sug-
gesting that it serves tomethylate a protein, smallmolecule
or nucleic acid within mitochondria. Interestingly, a com-
plex I subunit,NDUFB3,hasbeen reported tobemethylated
on at least twohighly conservedhistidines.48 This raises the
interesting possibility that C20orf7methylates this subunit
as a requisite step in the complex I assembly process.
Four complex I assembly factors in which mutations
cause complex I deﬁciency in humans have been identiﬁed
previously, namely, NDUFAF2, NDUFAF1, C6orf66,11 and
our recent identiﬁcation of C8orf38.29 NDUFAF2 (B17.2L)
appears to function in a late stage of complex I assembly.
It is not present in the holoenzyme but is associated with
a subcomplex of ~830 kDa that accumulates in patients
withmutations in theNDUFS4 subunit.26,49 This subassem-
bly is a productive intermediate in complex I assembly
because import of the missing subunit restores complex I
assembly.38 NDUFAF1 (CIA30) associates with complex I
at earlier stages (500–850 kDa subcomplexes)27 whereas
the roles of C6orf6628 and C8orf3829 are not yet clear.
C20orf7 appears to function at an early step in the com-
plex I assembly process but in a different manner to CIA30.
C20orf7 is involved in the assembly of an early intermedi-
ate of ~400 kDa, which contains the ND1 subunit, whereas
CIA30 appears to associate with assembly intermediates
that contain the ND2 subunit. The localization ofr 10, 2008
C20orf7 to themitochondrial inner membrane, disruption
of complex I activity upon silencing of its expression, and
the lethal neonatal complex I deﬁciency arising from a
mutation in the coding sequence of C20orf7, strongly
conﬁrm its role as a bona ﬁde complex I assembly factor.
Other putative complex I assembly factors have also
been identiﬁed but have not yet been shown to cause com-
plex I deﬁciency in humans. Ecsit has been reported to
interact with CIA30 in 500 kDa and 850 kDa complexes
and its knockdown resulted in severe impairment of com-
plex I assembly and mitochondrial function.50 Deﬁciency
of apoptosis-inducing factor (AIF) in the harlequin mutant
mouse causes a complex I assembly defect.51 Prohibitin
and PTCD1, the human ortholog of the CIA84 Neurospora
crassa complex I assembly factor, have also been identiﬁed
as possible assembly factors of complex I.11,51–53
Assembly factors could potentially be associated with
other pathways or diseases because dual roles have been
Figure 7. Complex I Assembly Is Im-
paired in Patient Cells
(A) After radiolabeling of mtDNA-encoded
subunits, control (lanes 1–4), or patient
A4 (lanes 5–8) fibroblasts were chased for
various times as indicated. Mitochondria
were isolated, solubilized in 1% Triton
X-100, and subjected to BN-PAGE followed
by phosphorimage analysis. Complex I (CI),
the complex III homodimer (CIII2), com-
plex IV (CIV), and complex V (CV) are
indicated.
(B) BN-PAGE and western blot indicating
the steady-state levels of the respiratory
complexes in mitochondria from control
(lanes 9, 11, 13, and 15) and patient A4
(lanes 10, 12, 14, and 16) fibroblasts.
(C) 2D-PAGE analysis of radiolabeled
mtDNA-encoded subunits from control
(left panels), patient A4 (middle panels),
and patient P (NDUFAF1 defect, right
panels) fibroblasts at different chase
times. Mitochondria were isolated, solubi-
lized in 1% Triton X-100, and subjected
to BN-PAGE in the first dimension followed
by SDS–PAGE in the second dimension and
phosphorimager analysis. The positions of
ND1 and ND2 are indicated.
reported for Ecsit,54 B17.2L,55 and
C6orf66.56 These are also involved
in regulating cell proliferation. As far
as we know, no other roles have as
yet been reported for C20orf7, al-
though it was identiﬁed as being
downregulated in a microarray ex-
pression analysis of cells treated with
heteroaromatic quinols possessing
antitumor activity.57
In conclusion, we have identiﬁed C20orf7 as a complex I
assembly factor andmutations in C20orf7 as a new cause of
complex I deﬁciency. It is likely that many more assembly
factors of complex I may be identiﬁed, bearing in mind
that complex IV with only 13 subunits requires more
than 15 assembly factors for its assembly.58 Further studies
are needed to incorporate known and unidentiﬁed com-
plex I assembly factors into a more complete complex I
assembly model. Identiﬁcation of additional assembly
factors remains a challenge but should increase our under-
standing not only of complex I biogenesis but also of
mitochondrial involvement in other common pathways
or diseases.
Supplemental Data
Supplemental Data include one table and can be found with this
article online at http://www.ajhg.org/.
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